A prospective, randomized, comparative open label study to evaluate efficacy and safety of Cysteamine 5% cream with Hydroquinone 4 % cream in patients with Melasma.

Cutis Institute of Dermatology0 个研究点目标入组 0 人开始时间: 待定最近更新: 2024年5月27日

试验速览

暂无简介。

•Patients who meet following criteria will be randomized in the study-
•1. Indian adult subjects aged 18 to 60 years
•2. Healthy subjects (no infectious and evolutive pathology which could make the subject vulnerable and stop the study, no pathology which could interfere with the study, no symptom in the process of an exploratory check-up)
•3. With healthy intact skin on the studied anatomic unit (free of eczema, wounds, inflammation)
•4. Patients willing to provide informed consent

•Patients who do not meet following criteria will be randomized in the study-
•1. Being pregnant or breastfeeding or having stopped to breastfeed in the past three months.
•2. Having refused to give consent by not signing the consent form.
•3. Taking part in another study liable to interfere with this study.
•4. Being insulin-dependent diabetic or non-insulin-dependent diabetic with a recent therapy (less than 6 months)
•5. Having progressive asthma.
•6. Being epileptic.
•7. Having non-stabilized thyroid disease (requirement of a stabilized treatment for at least 6 months)
•8. Having cutaneous hypersensitivity to study ingredients
•9. Having a diagnosed or highly probable allergy to one or several compounds of cosmetic products.
•10. Following a chronic medical treatment comprising any of the following products: aspirin-based products, anti-inflammatories, anti-histamines, corticosteroid therapy, taken by general or local routes (the only medication permitted is paracetamol)

发起方

Cutis Institute of Dermatology